Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18863632 | 0.71 | CSNK2A1 (0.44) | CDK2CSNK2A1 | |
| SCHEMBL23152044 | 0.70 | CDK2 (0.38) | CDK2CHEK1CCNA2CCNA1CSNK2A1 | |
| SCHEMBL7446616 | 0.69 | CDK2 (0.40) | CDK2CHEK1CCNA2CCNA1CSNK2A1 | |
| SCHEMBL10044343 | 0.68 | CDK2 (0.36) | CDK2CHEK1CCNA2CCNA1CSNK2A1 | |
| SCHEMBL14194706 | 0.67 | CDK2 (0.33) | CDK2CHEK1CCNA2CCNA1CSNK2A1 | |
| SCHEMBL17781287 | 0.64 | KDM4E (0.55) | CDK2CCNA2 | |
| SCHEMBL7438391 | 0.62 | CDK2 (0.40) | CDK2CHEK1CCNA2CCNA1CSNK2A1 | |
| SCHEMBL5926222 | 0.61 | CDK2 (0.41) | CDK2CHEK1CCNA2CCNA1CSNK2A1 | |
| SCHEMBL18526195 | 0.61 | CHEK1 (0.41) | CDK2CHEK1CCNA2CCNA1GSK3B | |
| SCHEMBL14050801 | 0.61 | CDK2 (0.50) | CDK2CHEK1CCNA2CCNA1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059827-B2 | Compounds and compositions useful for treating disorders related to NTRK | BLUEPRINT MEDICINES CORPORATION (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059827-B2 | Compounds and compositions useful for treating disorders related to NTRK | NTRK2, NTRK3, NTRK1 | CDK2 1703/4885CHEK1 1181/4885CCNA2 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.